Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Dr. Jean-Pierre Bizzari

<< Previous

Bullboard Posts

Next >>

Comment by venture009on Dec 14, 2023 4:37pm

142 Views

Post# 35785487

RE:RE:RE:RE:RE:RE:Dr. Jean-Pierre Bizzari

Our current BofD have very impressive credentials too, and how has that worked out so far? Reverse split, Anson deal errosion of shareholder value, many medical officers and where is de Guttadauro, etc. For once I would like this company to focus completely on increasing the share price and not expanding the science. 25 years already! Announcing a partner deal or a buyout would be the minimum expectation.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments